A5075054175- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Alzheimer's disease research and treatments
- Lung Cancer Diagnosis and Treatment
- Adipose Tissue and Metabolism
- Cholinesterase and Neurodegenerative Diseases
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Pancreatitis Pathology and Treatment
- Tryptophan and brain disorders
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Mitochondrial Function and Pathology
- Metastasis and carcinoma case studies
- Cardiovascular Disease and Adiposity
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Medicinal Plants and Neuroprotection
- Metabolomics and Mass Spectrometry Studies
- Head and Neck Cancer Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
Sichuan University
2007-2025
Sun Yat-sen University
2016-2025
Sun Yat-sen University Cancer Center
2016-2025
Shanghai Skin Disease Hospital
2025
Tongji University
2025
Merck & Co., Inc., Rahway, NJ, USA (United States)
2017-2024
Center for High Pressure Science & Technology Advanced Research
2021-2024
Fudan University Shanghai Cancer Center
2024
Shanghai Institute of Hematology
2024
Chinese PLA General Hospital
2013-2023
First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment choice. The addition to resulted in significantly higher rates response and longer progression-free survival than alone phase 2 trial.
Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall (OS) compared with platinum-based chemotherapy in patients previously untreated advanced non–small-cell lung cancer (NSCLC) a programmed death ligand 1 tumor proportion score of 50% or greater without EGFR/ALK aberrations. We report an updated OS tolerability analysis, including analyses adjusting for potential bias introduced by crossover from to...
In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free (PFS) compared with placebo in patients metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680).Patients were randomly assigned (2:1) to receive pemetrexed platinum (n = 410) or 206) every 3 weeks for 4 cycles,...
Among patients with resectable early-stage non–small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either alone. Download PDF of the Research Summary. We conducted randomized, double-blind, phase 3 trial to evaluate pembrolizumab in NSCLC. Participants stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned 1:1 ratio receive (200 mg) placebo once every weeks, each which was given...
Triple-negative breast cancer (TNBC) is an aggressive subtype of cancer, and there no approved targeted therapy. We studied the expression programmed cell death protein 1 (PD-1) its ligand (PD-L1) in TNBC.Full-face sections from 136 TNBC cases without neoadjuvant therapy between 2004 2013 were stained evaluated for immune PD-1 staining stromal or tumoral PD-L1 using H-score (staining percentage × intensity). Nottingham histologic grade, lymphovascular invasion (LVI), mitotic count,...
Hashimoto's thyroiditis (HT) is considered to be mediated mainly by Th1 cells, but it not known whether Graves' disease (GD) associated with or Th2 predominance. Th17 a novel subset of Th play crucial role in the pathogenesis various autoimmune disorders. In present study, expression IL-17A and IFN-γ was investigated patients HT GD. mRNA peripheral blood mononuclear cells (PBMC) from 43 thyroid (AITD) tissues 40 AITD were measured real-time qRT-PCR. The protein IL-23p19 examined...
Programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein (PD-1) modulate antitumor immunity are major targets of checkpoint blockade immunotherapy. However, clinical trials anti-PD-L1 anti-PD-1 antibodies in breast cancer demonstrate only modest efficacy. Furthermore, specific PD-L1 contributions various tissue compartments to remain incompletely elucidated. Here we show that expression is markedly elevated mature adipocytes versus preadipocytes. Adipocyte prevents...
Abstract In brains of Alzheimer’s disease (AD), reactive oxygen species (ROS) levels are significantly higher than that healthy brains. Evidence suggests that, during AD onset and progression, a vicious cycle revolves around amyloid beta (Aβ) production, aggregation, plaque formation, microglia/immunological responses, inflammation, ROS production. this cycle, play central role, H 2 O is one the most important species. report, we have designed fluorescent imaging probe CRANAD-88, which...
Objectives This study was designed to estimate the performance of textural features derived from contrast-enhanced CT in differential diagnosis pancreatic serous cystadenomas and mucinous cystadenomas. Methods Fifty-three patients with cystadenoma 25 were included. Textural parameters neoplasms extracted using LIFEx software, analyzed random forest Least Absolute Shrinkage Selection Operator (LASSO) methods. Patients randomly divided into training validation sets a ratio 4:1; method adopted...
9013 Background: Pembro + chemo significantly improved OS and PFS over alone had manageable safety as 1L therapy for metastatic nonsquamous NSCLC in the KEYNOTE-189 study (NCT02578680). The benefit was observed irrespective of PD-L1 TPS. We present updated based on longer follow-up and, first time, PFS2. Methods: Eligible pts were randomized 2:1 to pembro (n = 410) or placebo 206) pemetrexed carboplatin cisplatin 4 cycles followed by up 35 maintenance pemetrexed. Pts arm could crossover upon...
MicroRNAs (miRNAs) are short non-coding RNA molecules that play a significant role in many types of cancers including breast cancer. In the current study, we evaluated expression levels microR-10b (miR-10b) 115 cancer patients from Sichuan Cancer Center. Real time reverse transcription-PCR was used to assess miR-10b expression. Clinical data disease stage, survival status, age, ER/PR/HER2 molecular subtypes, tumor size, lymph node status and Ki-67 were correlated with levels. Our showed is...
The role of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway in the proliferation and apoptosis human colon cancer cells was studied. transduction process ERK/MAPK inhibited using methyl ethyl ketone (MEK) inhibitor U0126. Promoting effect hepatocyte growth factor (HGF) on detected via Cell Counting Kit 8 (CCK8), cycle were flow cytometry, migration wound healing assay. results revealed that after drug treatment for 48 h, there statistically...
Background: Marrow adipose tissue (MAT) has been shown to be vital for regulating metabolism and maintaining skeletal homeostasis in the bone marrow (BM) niche. As a reflection of BM remodeling, MAT is highly responsive nutrient fluctuations, hormonal changes, metabolic disturbances such as obesity diabetes mellitus. Expansion also strongly associated with loss mice humans. However, regulation plasticity remains poorly understood, does mechanism that links changes adiposity remodeling....
A series of novel quinoline-O-carbamate derivatives was rationally designed for treating Alzheimer's disease (AD) by multi-target-directed ligands (MTDLs) strategy. The target compounds were synthesised and evaluated AChE/BuChE inhibition anti-inflammatory property. in vitro activities showed that compound 3f a reversible dual eeAChE/eqBuChE inhibitor with IC50 values 1.3 µM 0.81 µM, respectively. Moreover, displayed good property decreasing the production IL-6, IL-1β NO. In addition,...
LBA100 Background: In patients (pts) with NSCLC, pembrolizumab (pembro) has shown efficacy as monotherapy in the adjuvant (adj) and advanced settings combination chemotherapy(chemo) metastatic disease. KEYNOTE-671 (NCT03425643), evaluated addition of pembro to platinum-based chemo neoadjuvant therapy followed by resection vs placebo adj early stage NSCLC. Methods: Eligible pts II, IIIA, or IIIB (N2) resectable NSCLC per AJCC v8 ECOG PS 0-1 were randomized 1:1 4 cycles 200 mg + cisplatin...
Abstract Background Most conventional methods for delivering chemotherapeutic agents fail to achieve therapeutic concentrations of drugs, despite reaching toxic systemic levels. Novel controlled drug delivery systems are designed deliver drugs at predetermined rates predefined periods the target organ and overcome shortcomings formulations therefore could diminish side effects improve life quality patients. Thus, a suitable system is extremely important chemotherapy. Results A novel...
In hepatocellular carcinoma (HCC), CD133+/CD44+ cells are one subgroup with high stemness and responsible for metastatic relapse resistance to treatment. Our previous studies have demonstrated that osteopontin (OPN) plays critical roles in HCC metastasis. We further investigated the molecular mechanism underlying role of OPN regulating epigenetically explored possible targeting strategy.CD133+/CD44+ sorting from cell lines tissues was used investigate effects knockdown on stemness. iTRAQ...
A suitable TSPO PET ligand may visualize and quantify neuroinflammation in a living brain. Herein we report 18F-ligand, [18F]2 ([18F]FDPA), is radiolabeled high yield specific activity based on our spirocyclic iodonium ylide (SCIDY) strategy. demonstrated saturable binding to TSPO, substantially elevated brain uptake, slow washout of bound signal the preclinical models (cerebral ischemia Alzheimer's disease).